264 related articles for article (PubMed ID: 16529882)
1. Abuse deterrent formulations and the Controlled Substances Act (CSA).
Sapienza FL
Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S23-30. PubMed ID: 16529882
[TBL] [Abstract][Full Text] [Related]
2. Research design strategies to evaluate the impact of formulations on abuse liability.
McColl S; Sellers EM
Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S52-62. PubMed ID: 16554125
[TBL] [Abstract][Full Text] [Related]
3. Risk management and post-marketing surveillance of CNS drugs.
Henningfield JE; Schuster CR
Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S56-64. PubMed ID: 19767155
[TBL] [Abstract][Full Text] [Related]
4. Principles of assessment of abuse liability: US legal framework and regulatory environment.
Rocha BA
Behav Pharmacol; 2013 Sep; 24(5-6):403-9. PubMed ID: 23820327
[TBL] [Abstract][Full Text] [Related]
5. National addictions vigilance intervention and prevention program (NAVIPPRO): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuse.
Butler SF; Budman SH; Licari A; Cassidy TA; Lioy K; Dickinson J; Brownstein JS; Benneyan JC; Green TC; Katz N
Pharmacoepidemiol Drug Saf; 2008 Dec; 17(12):1142-54. PubMed ID: 18932173
[TBL] [Abstract][Full Text] [Related]
6. Regulatory challenges for new formulations of controlled substances in today's environment.
McCormick CG
Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S63-7. PubMed ID: 16567060
[TBL] [Abstract][Full Text] [Related]
7. Monitoring risk: post marketing surveillance and signal detection.
Dart RC
Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S26-32. PubMed ID: 19748743
[TBL] [Abstract][Full Text] [Related]
8. Formulation considerations for the development of medications with abuse potential.
Mansbach RS; Moore RA
Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S15-22. PubMed ID: 16472940
[TBL] [Abstract][Full Text] [Related]
9. Debating the Controlled Substances Act.
Spillane JF
Drug Alcohol Depend; 2004 Oct; 76(1):17-29. PubMed ID: 15380285
[TBL] [Abstract][Full Text] [Related]
10. The Diversion of Ultram, Ultracet, and generic tramadol HCL.
Inciardi JA; Cicero TJ; Munoz A; Adams EH; Geller A; Senay EC; Woody GE
J Addict Dis; 2006; 25(2):53-8. PubMed ID: 16785220
[TBL] [Abstract][Full Text] [Related]
11. Risk evaluation and mitigation strategies for drugs with abuse liability: public interest, special interest, conflicts of interest, and the industry perspective.
Wright C; Schnoll S; Bernstein D
Ann N Y Acad Sci; 2008 Oct; 1141():284-303. PubMed ID: 18991964
[TBL] [Abstract][Full Text] [Related]
12. Risk identification, risk assessment, and risk management of abusable drug formulations.
Wright C; Kramer ED; Zalman MA; Smith MY; Haddox JD
Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S68-76. PubMed ID: 16581201
[TBL] [Abstract][Full Text] [Related]
13. Development of opioid formulations with limited diversion and abuse potential.
Fudala PJ; Johnson RE
Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S40-7. PubMed ID: 16564141
[TBL] [Abstract][Full Text] [Related]
14. Schedules of controlled substances; placement of 2,5-dimethoxy-4-(n)-propylthiophenethylamine and N-benzylpiperazine into Schedule I of the Controlled Substances Act. Final rule.
Drug Enforcement Administration (DEA), Department of Justice
Fed Regist; 2004 Mar; 69(53):12794-7. PubMed ID: 15029891
[TBL] [Abstract][Full Text] [Related]
15. The development of a comprehensive risk-management program for prescription opioid analgesics: researched abuse, diversion and addiction-related surveillance (RADARS).
Cicero TJ; Dart RC; Inciardi JA; Woody GE; Schnoll S; Muñoz A
Pain Med; 2007 Mar; 8(2):157-70. PubMed ID: 17305687
[TBL] [Abstract][Full Text] [Related]
16. Ephemeral profiles of prescription drug and formulation tampering: evolving pseudoscience on the Internet.
Cone EJ
Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S31-9. PubMed ID: 16458455
[TBL] [Abstract][Full Text] [Related]
17. Schedules of controlled substances: rescheduling of buprenorphine from schedule V to schedule III. Final rule.
Drug Enforcement Administration (DEA), Department of Justice
Fed Regist; 2002 Oct; 67(194):62354-70. PubMed ID: 12369590
[TBL] [Abstract][Full Text] [Related]
18. A regulatory perspective on the abuse potential evaluation of novel stimulant drugs in the United States.
Calderon SN; Klein M
Neuropharmacology; 2014 Dec; 87():97-103. PubMed ID: 24727212
[TBL] [Abstract][Full Text] [Related]
19. Schedules of controlled substances: placement of 5-methoxy-N,N-dimethyltryptamine into Schedule I of the Controlled Substances Act. Final rule.
Drug Enforcement Administration (DEA), Department of Justice
Fed Regist; 2010 Dec; 75(243):79296-300. PubMed ID: 21171485
[TBL] [Abstract][Full Text] [Related]
20. Definition of "positional isomer" as it pertains to the control of schedule I controlled substances. Final rule.
Drug Enforcement Administration (DEA), Department of Justice
Fed Regist; 2007 Dec; 72(231):67850-2. PubMed ID: 18064769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
